India's CDSCO has warned pharma firms against promoting prescription weight-loss drugs (GLP-1s) via surrogate or digital ads, ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

Fourth quarter results reflect meaningful progress in transformation journey Ian Bickley appointed Chairman and Chief ...

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has warned pharmaceutical companies against direct or indirect promotion of prescription weight-loss medicines, ...

As blockbuster weight-loss drugs surge in India, regulators warn that "awareness campaigns" may be blurring the line between public health messaging and pharmaceutical marketing. The arrival of ...

The Central Drugs Standard Control Organization (CDSCO) has issued an advisory cautioning pharmaceutical companies against direct or indirect promotional activities related to ...

The CDSCO advisory bars direct and indirect promotion of GLP-1 weight-loss drugs, including influencer campaigns and awareness content that create brand recall among consumers ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for prescription-only drugs. The regulator in an advisory ...

CDSCO issues advisory against promotional activities for anti-obesity, metabolic disorder drugs: Our Bureau, New Delhi Thursday, March 12, 2026, 12:45 Hrs [IST] The Central Drugs ...